m6A-Targeted Cancer Therapy: Molecular Targets, Inhibitors, and Nanodelivery Strategies Authors: Chenyu Li, Yuan Guo, Wenjun Jiang, Wei Xie, Yao Yao Published: 2026 ABSTRACT Abstractm6A methylation modification, a widespread RNA post-transcriptional modification in eukaryotes, has been shown to play a crucial role in various biological processes, including gene expression regulation, cell proliferation and differentiation. By regulating RNA stability, translation, and degradation, m6A can influence the expression of oncogenic and tumor-suppressive transcripts and thereby contribute to cancer initiation and progression. In recent years, m6A-targeted therapy has emerged as a promising approach in cancer treatment, particularly with the development of m6A inhibitors and the integration of nano-delivery technologies, which have demonstrated significant therapeutic potential. This review summarizes recent advances in m6A-targeted cancer therapy, with emphasis on small-molecule inhibitors and RNA-based strategies targeting m6A regulators, and highlights their integration with nanocarriers, including lipid nanoparticles, polymeric nanoparticles, and extracellular vesicle-based systems, to improve drug stability, pharmacokinetic properties, tumor accumulation, and therapeutic selectivity. This integrated perspective highlights the emerging role of nanodelivery in advancing m6A-targeted cancer therapy and provides a framework for understanding its therapeutic potential. Despite these advances and promising preclinical evidence, the clinical translation of m6A-targeted therapies remains limited, with challenges related to drug specificity, delivery optimization, and the complexity of m6A regulatory networks. Finally, the article envisions future research directions, emphasizing the integration of interdisciplinary technologies, and predicts the broad prospects of m6A-targeted therapy in precision cancer treatment. Introduction The m6A methylation modification is a widespread form of RNA modification in eukaryotes, and is the most abundant internal modification of mRNA.1 This modification plays a crucial role in a variety of RNA-related biological processes, including RNA transcription, 3’ end processing, nuclear export, translational regulation, and RNA stabilization.2 Compared with many other RNA modifications, the dynamic and reversible nature of m6A, together with its broad effects on RNA stability, translation, and degradation, provides multiple opportunities for therapeutic intervention in cancer.3 The regulatory role of m6A methylation is essential in gene expression control, with significant implications in tumor initiation and progression.4,5 Importantly, dysregulation of m6A regulators can alter the expression and stability of oncogenic and tumor-suppressive transcripts, highlighting the therapeutic potential of targeting m6A in cancer. Recent studies have demonstrated that m6A methylation-related drugs (eg, m6A methylation modification inhibitors) have significant therapeutic effects on cancer.5,6 Inhibitors of m6A methylation modification primarily target “writers” and “erasers” to reduce or increase intracellular m6A levels. For example, the FTO (fat mass and obesity-associated protein) inhibitor FB23-2 effectively inhibits the proliferation and induces apoptosis in acute myeloid leukemia cells.7 Other m6A-targeted agents have also shown promising therapeutic effects in different types of cancer.8,9 However, despite the progress, challenges remain in translating these findings into effective clinical therapies. Current drugs targeting m6A modification often face limitations such as poor targeting specificity, high toxicity, and unfavorable pharmacokinetic properties. These issues undermine their clinical efficacy and safety, underscoring the need for innovative therapeutic strategies. In particular, the limited stability and unfavorable distribution of some m6A-targeted agents may result in insufficient drug exposure at tumor sites and unintended effects on normal tissues, thereby restricting their therapeutic efficacy. To address these limitations, the development of nanocarrier-based delivery strategies for m6A-targeted agents has emerged as a promising approach. Nanocarriers, such as lipid nanoparticles, polymeric micelles, and dendrimers, offer the advantage of protecting therapeutic agents from premature degradation, improving their pharmacokinetic properties, and facilitating their accumulation in tumor tissues.10,11 Recent advances in nanomaterial-based biomedical strategies have further demonstrated the potential of engineered nanoplatforms to modulate the biological microenvironment, enhance therapeutic delivery, and improve treatment efficacy, providing valuable insights for the development of nanodelivery systems for m6A-targeted cancer therapy.12,13 Moreover, these systems can be engineered to release their payloads in a controlled manner, while surface functionalization with targeting ligands or tumor-responsive components may further enhance selective delivery to tumor cells and reduce systemic exposure. Recent studies have demonstrated that combining m6A methylation-related drugs with nanocarrier-based delivery systems can significantly improve drug targeting and delivery efficiency. For example, the encapsulation of m6A inhibitors in nanoparticles has been shown to enhance their accumulation at tumor sites, reducing off-target effects and improving therapeutic outcomes.14 Additionally, such delivery systems can provide sustained drug release, thereby maintaining effective drug concentrations and improving drug exposure at tumor sites. While previous reviews have mainly focused on the molecular mechanisms of m6A regulation and m6A-targeted therapeutic agents, relatively less attention has been given to their integration with nanodelivery strategies. Therefore, this review summarizes recent advances in m6A-targeted cancer therapy, with particular emphasis on the development of m6A-modulating agents and their combination with nanodelivery systems to improve drug selectivity, pharmacokinetic properties, tumor-specific delivery, and therapeutic efficacy. To identify relevant and recent literature, a literature search was conducted in PubMed and Web of Science using combinations of the keywords “m6A”, “N6-methyladenosine”, “cancer”, “m6A inhibitor”, “m6A-targeted therapy”, and “nanodelivery”, with the search updated through May 2026. Additional relevant studies were identified from the reference lists of selected articles. Mechanism of m6A Methylation Modification m6A modification primarily occurs at the RRACH sequence in RNA and is highly enriched in the stop codon, 3’-UTR region, and long intronic regions. In this modification process, methyltransferases act as “writers”, catalyzing the methylation of the nitrogen atom at position 6 of adenine in RNA, facilitating the formation of m6A. Specific “writers” include the METTL3 and METTL14 complex, which, in collaboration with the WTAP protein, precisely add the methyl group to the RNA molecule.15,16 In contrast, demethylases act as “erasers”, reversing this process primarily by removing the methyl groups from RNA. Representative “eraser” enzymes include FTO and ALKBH5 (α-ketoglutarate-dependent demethylase). In addition, the recognition of m6A modification relies on “reader” proteins, which specifically recognize and bind to m6A methylation sites, regulating various functions of RNA such as stability, translation, splicing, and degradation. Important “reader” proteins include YTHDF1, YTHDF2, YTHDC1, and IGF2BP, among others, which regulate these processes through their interactions with m6A-modified RNA.17,18 Through the coordinated action of these three components, the dynamic balance of m6A modification is maintained, precisely regulating the biological functions of RNA (Figure 1). Beyond the basic writer–eraser–reader framework, m6A regulation involves a dynamic interplay among these regulators that determines the fate and functional consequences of m6A-modified RNA. The coordinated regulation of m6A deposition, removal, and recognition can affect RNA stability, translation efficiency, splicing, degradation, and subcellular localization, thereby linking m6A modification to diverse cellular processes. Importantly, the functional outcome of m6A modification is highly context-dependent and can vary according to the specific RNA substrate, regulatory factor, and cellular environment. Figure 1m6A RNA modification mechanism. This diagram depicts the m6A modification process. Writers (METTL3, METTL14, WTAP, VIRMA, RBM15, ZC3H13, METTL16) install m6A on RNA. Erasers (FTO, ALKBH5, ALKBH3) remove m6A, and readers (YTHDC1, YTHDC2, YTHDF1, YTHDF2, YTHDF3, HNRNPA2/B1, HNRNPC, IGF2BPs, eIF3) recognize m6A to regulate RNA splicing, translation, degradation, and stability. The coordinated actions of these regulators dynamically determine the fate and functional consequences of m6A-modified RNA.A two-compartment cartoon shows RNA molecules moving between a blue nucleus and a pink cytoplasm. Small colored dots on the RNA indicate a cap and a methyl mark, with an RRACH motif labeled as the modification site. In the nucleus, oval protein complexes are grouped above the RNA to represent enzymes that add or remove the mark, while boxed proteins bound to RNA are linked to outcomes such as RNA splicing/export, splicing and pri-miRNA processing. In the cytoplasm, additional boxed RNA-binding proteins are shown next to labeled processes including translation, degradation and stability control, with arrows indicating alternative fates. A legend at the bottom maps colors/shapes to RNA, cap, methyl mark and the three regulator classes.Schematic of nuclear and cytoplasmic proteins acting on methyl-marked RNA and its outcomes. m6A RNA modification mechanism. This diagram depicts the m6A modification process. Writers (METTL3, METTL14, WTAP, VIRMA, RBM15, ZC3H13, METTL16) install m6A on RNA. Erasers (FTO, ALKBH5, ALKBH3) remove m6A, and readers (YTHDC1, YTHDC2, YTHDF1, YTHDF2, YTHDF3, HNRNPA2/B1, HNRNPC, IGF2BPs, eIF3) recognize m6A to regulate RNA splicing, translation, degradation, and stability. The coordinated actions of these regulators dynamically determine the fate and functional consequences of m6A-modified RNA. Methylation Transferase Methyltransferases are key enzymes in the m6A methylation process, responsible for adding a methyl group to specific positions in RNA molecules.19 The m6A methyltransferase complex is primarily composed of METTL3 and METTL14, along with the cofactor WTAP.20 This complex catalyzes the addition of a methyl group to the nitrogen atom at position 6 of the adenine residue in RNA molecules, thereby achieving m6A modification and regulating RNA stability, translation, and subsequent processing. In this complex, METTL3 acts as the catalytic subunit and plays a central role. METTL3 binds with METTL14 to form a stable heterodimeric complex, together recognizing specific RNA sequences (RRACH) and binding S-adenosylmethionine (SAM) as the methyl donor for the methylation reaction.21 METTL3 is the first characterized component of the m6A methyltransferase complex, primarily responsible for catalyzing the methylation reaction (Table 1). It directly interacts with the adenine residue in the RNA molecule, adding a methyl group to the nitrogen atom at position 6 of the RNA. METTL14 works synergistically with METTL3, providing structural support and ensuring the correct localization of METTL3, thereby precisely adding a methyl group at the RNA modification site.22 METTL14 also plays a supportive role in helping to form a stable complex and participates in the spatial localization of RNA modifications. In addition, WTAP, as a cofactor, assists in the localization of the METTL3 and METTL14 complex, ensuring the precise execution of the methylation reaction within the cell nucleus.23 Through this finely tuned regulatory mechanism, METTL3 and METTL14 jointly influence gene expression, cell differentiation, and the development of diseases such as cancer, making them important regulators of post-transcriptional RNA regulation. Table 1Functions of m6A Regulators in RNA MetabolismCategoryFactorFunctionReferenceWriterMETTL3Catalyzes m6A modification[20]METTL14Forms a methyltransferase complex with METTL3, working together to catalyze m6A modification.[20]WTAPActs as a regulatory subunit, recruiting METTL3 and METTL14 to specific RNA sites for m6A methylation.[23]VIRMARecruits METTL3 and METTL14, guiding m6A modification at specific RNA sites, promoting mRNA splicing and RNA processing.[24,25]METTL16Involved in m6A modification, regulating RNA splicing and translation.[26]RBM15/RBM15BDirects the METTL3-METTL14 complex to specific RNA sites for m6A modification.[15]ZC3H13Bridges WTAP to the mRNA-binding factor Nito.[27,28]EraserFTORemoves m6A modifications.[14,29]ALKBH5Removes m6A modifications.[30]ALKBH3Removes m6A modifications.[31]ReaderYTHDF1Promotes RNA translation[32]YTHDF2Promotes RNA degradation[33]YTHDF3Interacts with YTHDF1 to promote translation or with YTHDF2 to regulate mRNA degradation.[33]YTHDC1Promotes RNA splicing and export.[34]YTHDC2Enhances translation efficiency of target mRNA.[35]eIF3Promotes mRNA translation initiation.[15]IGF2BP1/2/3Binds to mRNA to promote stability and translation, regulating specific mRNA expression.[36]HNRNPA2B1Mediates mRNA splicing and primary microRNA processing[15]HNRNPCMediates mRNA splicing[15] Table 1Functions of m6A Regulators in RNA MetabolismCategoryFactorFunctionReferenceWriterMETTL3Catalyzes m6A modification[20]METTL14Forms a methyltransferase complex with METTL3, working together to catalyze m6A modification.[20]WTAPActs as a regulatory subunit, recruiting METTL3 and METTL14 to specific RNA sites for m6A methylation.[23]VIRMARecruits METTL3 and METTL14, guiding m6A modification at specific RNA sites, promoting mRNA splicing and RNA processing.[24,25]METTL16Involved in m6A modification, regulating RNA splicing and translation.[26]RBM15/RBM15BDirects the METTL3-METTL14 complex to specific RNA sites for m6A modification.[15]ZC3H13Bridges WTAP to the mRNA-binding factor Nito.[27,28]EraserFTORemoves m6A modifications.[14,29]ALKBH5Removes m6A modifications.[30]ALKBH3Removes m6A modifications.[31]ReaderYTHDF1Promotes RNA translation[32]YTHDF2Promotes RNA degradation[33]YTHDF3Interacts with YTHDF1 to promote translation or with YTHDF2 to regulate mRNA degradation.[33]YTHDC1Promotes RNA splicing and export.[34]YTHDC2Enhances translation efficiency of target mRNA.[35]eIF3Promotes mRNA translation initiation.[15]IGF2BP1/2/3Binds to mRNA to promote stability and translation, regulating specific mRNA expression.[36]HNRNPA2B1Mediates mRNA splicing and primary microRNA processing[15]HNRNPCMediates mRNA splicing[15] Functions of m6A Regulators in RNA Metabolism In addition, METTL16 is an RNA methyltransferase that participates in m6A modification, particularly methylating the A43 position of U6 small nuclear RNA and the 3′ UTR of mRNA.37 By regulating the homeostasis of SAM, METTL16 promotes the expression of MAT2A and maintains SAM levels under SAM-deprived conditions, influencing RNA methylation.38 Furthermore, METTL16 plays an important role in RNA splicing, regulating gene expression and stability. METTL16 interacts with multiple proteins, such as La protein, LARP7, and MEPCE, to promote the biogenesis of U6 small nuclear ribonucleoproteins (snRNP), participating in RNA processing and post-transcriptional regulation.39 VIRMA recruits the m6A methyltransferase complex (MTC) and catalyzes methylation of adenine near the 3′ UTR and stop codon in mRNA. It interacts with CPSF5 and CPSF6, involved in polyadenylation.24 Additionally, RBM15, RBM15B, and ZC3H13 are also key members of the m6A methyltransferase complex, playing crucial roles in the m6A methylation process.40 These proteins collaborate with other m6A methyltransferases to influence various cellular processes—such as gene expression, cell division, and metabolic regulation—through precise RNA methylation modifications. This provides a broader perspective on the regulatory network of m6A methylation and offers novel therapeutic targets for related diseases. Demethylase FTO is the first discovered m6A demethylase, identified in 2011.41 It belongs to the alpha-ketoglutarate-dependent dioxygenase family and catalyzes the m6A demethylation process. FTO utilizes Fe(II) and alpha-ketoglutaric acid to first oxidize m6A into N6-hydroxymethyladenosine (hm6A), then convert hm6A into N6-formyladenosine (f6A), and finally transform f6A into adenosine (A), completing the demethylation process.42 FTO regulates RNA stability by removing m6A modifications from RNA and plays an important role in cellular energy metabolism, fat accumulation, and obesity.7 Studies have shown that FTO is closely associated with the development of diseases such as diabetes and obesity, and is involved in the progression of certain cancers. Soon after, ALKBH5, as the second m6A demethylase, was discovered in 2013.43 Similar to FTO, ALKBH5 also belongs to the alpha-ketoglutarate-dependent dioxygenase family and participates in the m6A demethylation process. ALKBH5 plays an important role in embryonic development, neurodevelopment, and germ cell maturation. In the nervous system, ALKBH5 is essential for neuronal development and synaptic plasticity, and participates in regulating gene expression and stress responses.44 These findings fully indicate that m6A modification is a reversible process, and that FTO and ALKBH5 play a central role in the demethylation process and exert key regulatory functions in various biological functions. In addition, other studies have identified another m6A demethylase, ALKBH3,31 which may also complete the m6A demethylation process through a similar mechanism. Methylation-Recognizing Protein The functional interactions between m6A “writers” and “erasers” determine the dynamic and reversible regulation of m6A modifications. For biologically functional m6A-modified RNAs, they must be recognized by specific “readers” to exert distinct downstream effects. m6A methylation recognition proteins are proteins capable of specifically recognizing and binding to m6A-modified sites, primarily including the YTHDF family and the IGF2BP family.45 Additionally, the heterogenous nuclear ribonucleoprotein complex (HNRNPC, HNRNPA2B1) and the eukaryotic initiation factor eIF3 are also important m6A reader proteins.15 These reading proteins exhibit remarkably diverse functions, exerting crucial regulatory roles by recognizing and binding to m6A modifications at distinct sites within RNA molecules.46 Not only do these proteins influence RNA splicing processes—regulating alternative exon selection and the occurrence of alternative splicing—but they also interact with translational factors during translation to modulate RNA translation efficiency.47 Additionally, they participate in the nuclear transport of RNA, ensuring the proper localization and functional expression of RNA molecules within the cell.48 More importantly, these reader proteins also interact with RNA degradation mechanisms, further regulating gene expression and cellular functions by modulating RNA stability. Through these multi-layered actions, m6A reader proteins play a crucial role in biological processes such as gene expression regulation, development, stress responses, and disease onset. In human cells, the YTH structural family comprises YTHDF1-3 and YTHDC.1−249 Among these, YTHDF1-3 primarily recognize m6A-modified mRNA in the cytoplasm.50 YTHDF1 was first discovered to bind m6A sites near stop codons and enhance RNA translation efficiency through interactions with eIF3.51,52 YTHDF2 is the earliest discovered m6A reader protein and the most extensively studied m6A reader. Under normal physiological conditions or stress responses, YTHDF2 exerts its biological functions by promoting the degradation of m6A-modified RNA.53,54 YTHDF3 and YTHDF1 synergistically interact during the translation of m6A-methylated RNA, jointly enhancing translation efficiency. Additionally, YTHDF3 further promotes mRNA degradation through direct interaction with YTHDF2. Therefore, the interaction between YTHDF3 and YTHDF1 and YTHDF2 not only enhances the translation of m6A-methylated RNA at the translational level but also finely regulates the dynamic equilibrium of gene expression by modulating mRNA stability and degradation.55,56 YTHDC1 and YTHDC2 primarily function within the cell nucleus.57 Recent studies reveal that YTHDC1 promotes the transport of m6A-modified mRNA from the nucleus to the cytoplasm by interacting with SRSF3 and NXF1.58 This process influences RNA transport, enabling its smooth transfer from the nucleus to the cytoplasm for translation. Additionally, YTHDC2 regulates RNA translation efficiency by preferentially binding to m6A modifications within conserved motifs in RNA.35 The function of YTHDC2 not only enhances the translation efficiency of target mRNAs but also further modulates gene expression levels within cells by reducing the abundance of target mRNAs. The IGF2BP family primarily comprises IGF2BP1, IGF2BP2, and IGF2BP3, which play a crucial role in RNA metabolism within cells. Unlike the YTHDF family, the primary function of the IGF2BP family is to regulate mRNA expression levels by binding to m6A-modified RNA, recruiting RNA stabilizers, and thereby promoting mRNA stability.59,60 This process ensures effective translation of target mRNAs by prolonging their half-life and preventing degradation.61 The RNA stability regulation exerted by IGF2BP family members plays a crucial role in various biological processes, particularly in tumor progression.62 Studies indicate that the IGF2BP family enhances tumor cell proliferation, migration, and metastasis by promoting the stability of tumor-associated mRNAs.63 Due to their high expression in tumors and association with malignant phenotypes, members of the IGF2BP family represent potential therapeutic targets for cancer. Therefore, modulating the function of the IGF2BP family may offer novel strategies for cancer treatment. Additionally, members of the HNRNP family play key roles in RNA processing. HNRNPA2/B1 recognizes m6A modifications on specific pri-miRNA transcripts and interacts with Drosha and DGCR8, facilitating pri-miRNA processing.64 Similarly, HNRNPC and HNRNPG, upon recognizing m6A, regulate mRNA abundance and splicing, influencing RNA stability and gene expression. Mechanism of m6A Methylation in Tumors The impact of m6A methylation on tumors has become a key area of research, as it plays a crucial role in the initiation and progression of various cancers. Studies have shown that the expression levels of m6A-associated proteins directly influence tumor progression, exerting regulatory functions within tumors. m6A modification can promote tumor formation or, in some cases, suppress tumor growth, depending on the tumor type (Table 2). Therefore, studying the biological functions of m6A-regulated genes in different cancer types is essential for gaining deeper insights into the mechanisms of tumorigenesis. Table 2m6A RNA Methylation in Various CancersMoleculeCancerRole in CancerMechanismReferencesMETTL3AMLOncogeneMediates m6A modification on MYC, BCL2, and PTEN mRNAs and promoted their translation[65]HCCOncogeneImpacting the SCAP-cholesterol axis, suppressing CD8+ T cell activation[66]HCCOncogenePromotes tumor growth by enhancing the m6A modification and degradation of SOCS2 and STAT3.[67,68]BCOncogeneModifying LATS1 enhances glycolysis and promotes tumorigenesis.[69]GBMSuppressorRestrains GSC growth and stemness by promoting m6A methylation of ADAM19, leading to its downregulation.[70]METT14AMLOncogeneEnhances tumorigenesis by upregulating m6A and MYC/MYB expression.[71]HCCSuppressorMETTL14 regulates the Mettl14-USP48-SIRT6 axis, enhancing SIRT6 stability and inhibiting metabolic reprogramming[72]HCCSuppressorProduces shorter 3’ UTR isoforms (METTL14-US) through APA, inhibiting tumor formation by regulating stemness in HCC.[73]FTOAMLOncogeneSuppresses the expression of ASB2 and RARA, affecting AML cell differentiation.[74]HCCOncogeneUpregulates GPNMB expression, thereby promoting tumor formation and metastasis.[75,76]BCOncogeneRegulating the CYP27B1/1,25D3/STAT3 axis to promote breast cancer progression.[77]Cervical CancerOncogeneIncreases resistance to chemoradiotherapy by diminishing the m6A modification of β-catenin.[78]ALKBH5AMLOncogeneRegulates the TACC3 gene[79]BCOncogeneRegulating the FOXO1/SOD2 axis to promote cancer cell resistance.[80]GBMOncogeneEnhance the self-renewal, DNA repair capacity, and radiotherapy resistance of GBM stem cells.[81]YTHDF1HCCOncogeneEnhancing the translation of ATG2A/ATG14 activates autophagy and promotes HCC growth and metastasis.[82]YTHDF2GBMSuppressorPromoting the degradation of m6A-modified transcripts and inhibiting the expression of tumor-promoting genes, it exerts an anti-cancer effect[83]IGF2BP2BCOncogeneEnhancing the translation of key cell cycle regulatory factors such as CDK6.[84] Table 2m6A RNA Methylation in Various CancersMoleculeCancerRole in CancerMechanismReferencesMETTL3AMLOncogeneMediates m6A modification on MYC, BCL2, and PTEN mRNAs and promoted their translation[65]HCCOncogeneImpacting the SCAP-cholesterol axis, suppressing CD8+ T cell activation[66]HCCOncogenePromotes tumor growth by enhancing the m6A modification and degradation of SOCS2 and STAT3.[67,68]BCOncogeneModifying LATS1 enhances glycolysis and promotes tumorigenesis.[69]GBMSuppressorRestrains GSC growth and stemness by promoting m6A methylation of ADAM19, leading to its downregulation.[70]METT14AMLOncogeneEnhances tumorigenesis by upregulating m6A and MYC/MYB expression.[71]HCCSuppressorMETTL14 regulates the Mettl14-USP48-SIRT6 axis, enhancing SIRT6 stability and inhibiting metabolic reprogramming[72]HCCSuppressorProduces shorter 3’ UTR isoforms (METTL14-US) through APA, inhibiting tumor formation by regulating stemness in HCC.[73]FTOAMLOncogeneSuppresses the expression of ASB2 and RARA, affecting AML cell differentiation.[74]HCCOncogeneUpregulates GPNMB expression, thereby promoting tumor formation and metastasis.[75,76]BCOncogeneRegulating the CYP27B1/1,25D3/STAT3 axis to promote breast cancer progression.[77]Cervical CancerOncogeneIncreases resistance to chemoradiotherapy by diminishing the m6A modification of β-catenin.[78]ALKBH5AMLOncogeneRegulates the TACC3 gene[79]BCOncogeneRegulating the FOXO1/SOD2 axis to promote cancer cell resistance.[80]GBMOncogeneEnhance the self-renewal, DNA repair capacity, and radiotherapy resistance of GBM stem cells.[81]YTHDF1HCCOncogeneEnhancing the translation of ATG2A/ATG14 activates autophagy and promotes HCC growth and metastasis.[82]YTHDF2GBMSuppressorPromoting the degradation of m6A-modified transcripts and inhibiting the expression of tumor-promoting genes, it exerts an anti-cancer effect[83]IGF2BP2BCOncogeneEnhancing the translation of key cell cycle regulatory factors such as CDK6.[84] m6A RNA Methylation in Various Cancers Acute Myeloid Leukemia (AML) AML is one of the most prevalent hematologic cancers, characterized by significant genetic alterations and poor therapeutic outcomes.85 Recent studies have highlighted that METTL3, a pivotal methyltransferase involved in m6A RNA modification, plays a critical oncogenic role in AML by catalyzing methylation. Elevated METTL3 expression is observed in AML cells compared to normal hematopoietic cells, and this overexpression correlates with leukemia progression. Further investigation has revealed that depletion of METTL3 in AML cells induces differentiation and apoptosis, thereby hindering leukemia development.86 Notably, METTL3 regulates the m6A modification of key mRNAs such as MYC, BCL2, and PTEN, enhancing their translation and promoting AML progression.65 These findings underscore the significance of METTL3 in regulating mRNA stability and translation, which is essential for maintaining the leukemic phenotype. In addition, METTL14, which collaborates with METTL3, is also upregulated in AML cells and exerts a similar regulatory effect on leukemogenesis by promoting tumorigenesis through enhancing m6A modification and the expression of MYC and MYB.71 Studies have further highlighted FTO’s crucial oncogenic role in AML, suggesting that it could serve as a valuable therapeutic target for AML treatment. FTO exerts its oncogenic effects by targeting the tumor suppressor proteins ASB2 and RARA, both of which are involved in m6A demethylation. By reducing m6A modification in the mRNA transcripts of ASB2 and RARA, FTO suppresses their expression. These proteins play vital roles in regulating normal hematopoiesis and the differentiation of leukemia cells, especially in the presence of all-trans retinoic acid (ATRA), making FTO’s modulation of these pathways central to AML progression.74 Elevated expression levels of ALKBH5 are closely linked to AML progression. While ALKBH5 is crucial for the development and maintenance of AML and the self-renewal of leukemia stem cells (LSCs), it is not essential for normal hematopoietic function. At the molecular level, ALKBH5 promotes tumorigenesis in AML by post-transcriptionally regulating key targets such as TACC3, an oncogene with prognostic relevance across various cancers.79 Hepatocellular Carcinoma (HCC) Studies have shown that abnormal m6A modification is closely associated with HCC progression. Specifically, METTL3 expression levels are elevated in HCC patients, and METTL3 overexpression increases the m6A modification of the tumor suppressor SOCS2, thereby promoting HCC progression.67 Additionally, in NAFLD-HCC, METTL3 has also been confirmed to promote disease progression. METTL3 activity affects key pathways, such as the SCAP-cholesterol axis, suppressing CD8+ T cell.66 Additionally, studies have shown that METTL3 enhances the m6A modification and translation efficiency of STAT3 mRNA, activating the STAT3 signaling pathway, thereby promoting the proliferation, migration, and invasion of HCC cells.68 METTL14 plays a tumor-suppressive role in HCC, and its expression is strongly associated with patient prognosis. In HCC, METTL14 undergoes alternative polyadenylation (APA), producing shorter 3’UTR isoforms (METTL14-US) that lead to enhanced METTL14 expression. METTL14-US expression significantly reduces HCC stemness, as shown in both in vitro and in vivo models. Moreover, METTL14-US expression suppresses stem cell markers such as CD90 and CD44 in HCC cells, inhibiting their tumor-forming capacity. Thus, METTL14-US exerts its anti-tumorigenic effects by regulating stemness in HCC, and targeting METTL14 expression through APA regulation may be a promising therapeutic approach to inhibit HCC progression.73 Another study has shown that pri-miR126 is a direct target of METTL14, with m6A modification on pri-miR126 enabling its binding to DGCR8, thereby enhancing the maturation of miR126, a known tumor suppressor.87 Additionally, studies have shown that the Mettl14-USP48-SIRT6 axis is a key tumor-suppressive pathway in HCC. USP48 expression is downregulated in both diethylnitrosamine-induced mouse liver tumors and HCC. USP48 regulates HCC progression by binding to and stabilizing SIRT6 through K48-linked deubiquitination at specific sites (K33 and K128). This interaction impedes metabolic reprogramming, thereby hindering tumorigenesis.72 Other studies have shown that FTO influences the expression of genes such as GPNMB. FTO stabilizes GPNMB mRNA by removing m6A modifications, thereby enhancing protein expression. GPNMB is a key factor in HCC progression, activating oncogenic signaling pathways such as AKT, ERK, and WNT, which promote tumor growth and metastasis.75,76 There are also studies showing that in HCC, YTHDF1 is a hypoxia-induced m6A oncogenic factor that activates autophagy by enhancing the translation of ATG2A/ATG14, promoting tumor growth and metastasis.82 Breast Cancer (BC) In BC, METTL3, as an m6A writer, modifies LATS1 mRNA by adding m6A marks, which are then recognized by the m6A reader YTHDF2. This modification leads to a decrease in LATS1 mRNA stability and its protein expression, thereby activating the YAP/TAZ pathway in the Hippo signaling pathway. This activation promotes tumor growth and glycolysis in BC cells.69 In addition, FTO plays an important role in the development of breast cancer (BC). Studies confirm that FTO is an oncogene in BC, and its high expression is associated with poor prognosis in patients. Research has shown that FTO reduces the stability of CYP27B1 mRNA in an m6A-dependent manner. CYP27B1 is crucial for synthesizing the tumor-suppressive metabolite 1,25-dihydroxyvitamin D3 (1,25D3). By inhibiting CYP27B1 expression, FTO reduces 1,25D3 synthesis, thereby activating the STAT3 signaling pathway. This pathway further promotes the growth and progression of BC.77 The relationship between IGF2BP2 and breast cancer is significant, especially in triple-negative breast cancer (TNBC). IGF2BP2 is highly expressed in TNBC, and its role in promoting CDK6 translation significantly affects tumor growth and the progression of the G1/S phase in the cell cycle. Its upregulation leads to increased CDK6 protein levels, promoting TNBC cell proliferation and tumor development.84 In addition, ALKBH5-mediated m6A demethylation increases the stability of FOXO1 mRNA, leading to higher FOXO1 protein levels. FOXO1 then promotes the expression of SOD2, an enzyme that helps reduce ROS levels, contributing to cancer cell survival and chemoresistance in TNBC.80 Glioblastoma (GBM) GBM is a highly malignant primary brain tumor with an extremely high mortality rate. Studies have found that m6A RNA methylation plays a critical role in maintaining the stemness characteristics of glioblastoma stem cells (GSCs) and in promoting tumorigenesis. When the expression of METTL3 or METTL14 is suppressed, the proliferative and self-renewal capacities of GSCs are significantly enhanced; conversely, upregulation of METTL3 or inhibition of the demethylase FTO markedly attenuates these biological behaviors. Further m6A sequencing results indicate that downregulation of METTL3 or METTL14 reduces m6A modification on ADAM19 transcripts, thereby upregulating its expression and promoting the initiation and progression of GBM.70 In addition, the FTO inhibitor MA2 is able to restore m6A modification levels and significantly suppress GBM progression in both in vitro and in vivo models. Furthermore, studies have shown that YTHDF2 primarily plays an anti-cancer role in GBM. As a key m6A reader protein, YTHDF2 specifically recognizes and promotes the degradation of m6A-modified transcripts, thereby limiting the expression of various tumor-promoting genes.83 In GBM, downregulation of YTHDF2 leads to increased stability of oncogenic mRNA, which in turn promotes tumor cell proliferation, invasion, and GSCs’ self-renewal ability. In contrast, functional maintenance of YTHDF2 helps to inhibit tumor growth and stemness characteristics, suggesting its important anti-cancer regulatory role in the development of GBM. ALKBH5 also plays an important role in GBM by regulating the m6A methylation process, enhancing GSCs’ stem-like characteristics, DNA repair ability, and treatment resistance.81 Specifically, ALKBH5 stabilizes key mRNAs involved in DNA repair, such as FANCI, FANCD2, MKI67, and RAD51, by demethylating m6A modifications. This stability helps accelerate DNA repair and increases resistance to treatments like radiation. Therefore, ALKBH5 seems to promote GBM progression by enhancing GSCs’ DNA repair processes and self-renewal traits. Cervical Cancer Among gynecological cancers, cervical cancer is one of the most common types. It is typically caused by infection with the human papillomavirus (HPV). The majority of cervical cancer cases are cervical squamous cell carcinoma (CSCC). Studies indicate that FTO expression levels in CSCC tissues are significantly higher than in normal cervical tissues. As an m6A demethylase, FTO regulates RNA stability and translational efficiency by removing m6A modifications from mRNA transcripts. Specifically, FTO reduces the expression of β-catenin mRNA by diminishing its m6A modification, thereby enhancing tumor cell growth and survival while increasing their tolerance to radiotherapy and chemotherapy. Consequently, high FTO expression is closely associated with treatment resistance in cervical squamous cell carcinoma, making it a potential therapeutic target.78 Inhibiting FTO may help overcome resistance to radiotherapy and chemotherapy in cervical cancer, offering novel therapeutic approaches and strategies. Taken together, these findings highlight the context-dependent functions of m6A regulators in cancer. METTL3 and METTL14 promote AML progression, whereas their depletion enhances glioblastoma stem cell growth and self-renewal, indicating that the same regulators may exert opposite effects in different tumor contexts.88 Similarly, METTL14 acts as an oncogenic factor in AML but exhibits tumor-suppressive effects in HCC.89 FTO and ALKBH5 also show context-dependent functions, with both oncogenic and tumor-suppressive roles reported in different cancer types.90 These differences may depend on cancer type, downstream RNA substrates, and tumor microenvironment. Therefore, the therapeutic value of targeting a specific m6A regulator should be evaluated in a cancer-specific context rather than based solely on its expression level. Therapeutic Strategies Targeting m6A Methylation in Cancer m6A methylation inhibitors, as chemical molecules that regulate m6A methylation levels, have become a focus of research. By inhibiting m6A-related enzymes such as METTL3, METTL14, FTO, ALKBH5, and others, m6A inhibitors can alter the m6A modification patterns in tumor cells, thereby inhibiting tumor growth and metastasis. Increasing preclinical studies and preliminary clinical trials have shown that m6A inhibitors not only effectively reduce tumor cell proliferation, but may also enhance tumor sensitivity to conventional chemotherapy drugs and even restore tumor response to immunotherapy. Due to their targeted nature and relatively low side effects, m6A inhibitors provide a novel therapeutic strategy for cancer treatment. METTL3-METTL14 Inhibitors METTL3, as a key enzyme in m6A methylation, has been shown to play a crucial role in the initiation, progression, and metastasis of various cancers. Meanwhile, an increasing number of studies are focused on developing chemical molecules that can specifically inhibit the activity of METTL3. A study identified the first METTL3 catalytic inhibitor, STM2457 (Figure 2A), which exhibits good bioavailability and high selectivity.91 This inhibitor competitively binds to the SAM-binding site of METTL3, significantly inhibiting the methyltransferase activity of the METTL3/METTL14 complex,92 thereby reducing m6A modification levels in tumor cells. Functional studies show that STM2457 selectively inhibits the proliferation of AML cells, induces differentiation and apoptosis, and reduces the m6A modification of key oncogenic transcripts (such as MYC, HOXA10, etc), leading to a decrease in their translational efficiency (Figure 2B). In various in vivo models, METTL3 inhibition significantly suppressed leukemia progression, weakened the maintenance of leukemia stem cells, and prolonged survival, with minimal effects on the normal hematopoietic system. Other studies have also shown that STM2457 inhibits the growth of neuroblastoma tumors in vivo92 and the progression of prostate cancer.93 (Figure 2C and D). The study shows that UZH2 effectively inhibits the methyltransferase activity of METTL3 by competitively binding to the SAM-binding site. In in vitro experiments, UZH2 demonstrated significant inhibitory effects, with an IC50 of approximately 5 nM, indicating its strong inhibitory activity. UZH2 reduces m6A modification levels, thereby inhibiting the proliferation of tumor cells, and has the potential to be a candidate drug for the treatment of AML and other cancers.94 Figure 2(A) the chemical formula of STM2457; (B) STM2457 reduces the expression levels of BRD4, C-MYC, and SP1 in AML cells, Reproduced from [91] with permission from Springer Nature; (C) Mechanism diagram of STM2457 inhibiting neuroblastoma proliferation, Reproduced from [92] under the Creative Commons CC BY-NC license; (D) Mechanism diagram of STM2457 inhibiting prostate cancer progression, Reproduced from [93] under the CC BY-NC license. (Red arrows indicate molecular alterations induced by STM2457 treatment. Purple arrows represent changes caused by PARPi. Up‑arrows mean increase/promotion, and down‑arrows denote decrease/inhibition.).A scientific figure illustrates STM2457 as a METTL3 inhibitor. Panel A displays STM2457′s chemical structure. Panel B shows a western blot where BRD4, c-Myc and SP1 protein levels decrease with increasing STM2457 concentration, while GAPDH remains constant as a control. Panel C outlines two pathways: active METTL3/METTL14 mark m6A on differentiation-related mRNA, recruiting reader proteins that degrade mRNA and promote neuroblastoma growth. Inhibition of METTL3/METTL14 stabilizes mRNA, inhibiting growth and inducing differentiation. Panel D demonstrates STM2457 blocking METTL3/METTL14 on IGFBP3 RNA, increasing IGFBP3 protein, inactivating AKT, reducing proliferation and migration, leading to cell death. PARP inhibitor treatment enhances cell death via PARP pathway alterations.STM2457 structure, BRD4, c-Myc, SP1 reduction and cancer inhibition mechanisms in four-panel figure. (A) the chemical formula of STM2457; (B) STM2457 reduces the expression levels of BRD4, C-MYC, and SP1 in AML cells, Reproduced from [91] with permission from Springer Nature; (C) Mechanism diagram of STM2457 inhibiting neuroblastoma proliferation, Reproduced from [92] under the Creative Commons CC BY-NC license; (D) Mechanism diagram of STM2457 inhibiting prostate cancer progression, Reproduced from [93] under the CC BY-NC license. (Red arrows indicate molecular alterations induced by STM2457 treatment. Purple arrows represent changes caused by PARPi. Up‑arrows mean increase/promotion, and down‑arrows denote decrease/inhibition.). In addition to the aforementioned STM2457 and UZH2, several METTL3 inhibitors have been reported in recent years, spanning various categories including nucleoside-based, non-nucleoside-based, and natural products.8 Among them, Adenosine, one of the earliest METTL3 inhibitors, exhibits relatively weak inhibitory activity (IC50 = 495 μM) through competition with the SAM binding site, laying the foundation for the development of more effective inhibitors in subsequent research.8 CDIBA (N-(2-chlorobenzyl)-4-(dimethylamino)-3-methylphenylcarbamate) is a non-nucleoside compound that has been found to effectively inhibit the activity of METTL3. This compound interacts with the catalytic site of METTL3, inhibiting its methyltransferase activity, thereby reducing m6A modification levels and, to some extent, inhibiting the proliferation of tumor cells.95 In addition, Eltrombopag, a drug used to treat thrombocytopenia, has also shown inhibitory effects on METTL3. Studies have indicated that Eltrombopag interacts with METTL3, inhibiting its catalytic activity and subsequently affecting cell proliferation and growth. This finding provides a new perspective on the potential application of Eltrombopag in cancer treatment, particularly in the field of hematological tumors.96 Quercetin, as a natural product, has also been found to exhibit inhibitory effects on METTL3. Through virtual screening and experimental validation, quercetin has become an effective METTL3 inhibitor. It interferes with the catalytic site of METTL3, reducing m6A modification, thereby inhibiting the growth and spread of tumor cells. In particular, quercetin shows certain anti-tumor activity in the treatment of pancreatic cancer and gastric cancer.97 Finally, Elvitegravir, an antiviral drug used to treat HIV, has also been found to promote the degradation of METTL3. Elvitegravir interacts with the E3 ubiquitin ligase STUB1, facilitating the degradation of METTL3 and thereby reducing its levels in cells. This effect not only provides a new mechanism of action for HIV treatment but also suggests the potential application of Elvitegravir in the treatment of cancer and viral infections.98 With further understanding of METTL3 and the ongoing development of small molecule inhibitors, the clinical application potential of METTL3-targeted drugs in the future is highly promising. In addition to small molecule inhibitors, researchers have developed macromolecule inhibitors targeting the METTL3-METTL14 complex, which offer higher bioavailability. WD6305 is a PROTAC-based degrader specifically designed to target the METTL3-METTL14 complex. It works by linking the known METTL3 inhibitor UZH2 with the E3 ubiquitin ligase VHL ligand (S,R,S)-AHPC-Me, utilizing the bifunctional structure of PROTAC to recruit VHL. This leads to the tagging of METTL3 and METTL14, which are then degraded through the ubiquitin-proteasome system. Compared to traditional METTL3 inhibitors like UZH2, WD6305 not only inhibits the catalytic activity of METTL3 but also degrades the entire METTL3-METTL14 complex, significantly enhancing the degradation efficiency. Studies show that WD6305 exhibits stronger antiproliferative effects and induces apoptosis more effectively than UZH2 in multiple acute myeloid leukemia (AML) cell lines, especially in Mono-Mac-6 and MOLM-13 cells (Figure 3A).99 Another group of researchers, based on the crystal structure of METTL3-METTL14, designed a series of peptide sequences targeting two interaction interfaces between the proteins (interface loop, residues 462–479; helix a2, residues 435–447) and the substrate catalytic center (residues 534–541). These peptides were conjugated with the cell-penetrating peptide R9 for intracellular delivery, and through experimental screening, a biologically active peptide, RM3, was identified. RM3 targets METTL3, inhibits its enzymatic activity, and suppresses the proliferation and migration of cancer cells. To enhance the stability of the peptide and maintain its α-helix structure, the researchers further designed a stapled peptide inhibitor, RSM3. Experimental results show that RSM3 effectively reduces the mRNA methylation levels in cells, significantly inhibits the growth of various cancer cells, and induces apoptosis, demonstrating strong broad-spectrum anticancer activity. In mouse models of prostate and pancreatic cancers, RSM3 exhibited good antitumor effects and favorable safety. Compared to STM2457, RSM3 showed slightly better in vivo efficacy (Figure 3B).100 In conclusion, RSM3 holds great potential for application, offering a new approach for cancer treatment. Figure 3(A) The design diagram of PROTAC WD6306, Reproduced from [99] with permission from Elsevier. © 2023 Elsevier Ltd; (B) The design diagram of RSM3, Reproduced from [100] with permission from Wiley. (Blue downward arrows indicate decreased proliferation and migration, whereas red upward arrows indicate increased inflammation and apoptosis.).The image A shows the mechanism of PROTAC WD6305 targeting the METTL3-METTL14 complex. METTL3 and METTL14 are linked to PROTAC WD6305, which recruits VHL, E2 and E3 ligases, leading to ubiquitination and degradation by the proteasome. The METTL3-METTL14 complex is shown being degraded. The image B illustrates the action of RSM3, which enters cells and interferes with METTL3-METTL14, inhibiting enzyme activity and reducing RNA methylation. This leads to METTL3 degradation by proteasomes. The diagram indicates decreased proliferation and migration and increased inflammation and apoptosis, with arrows showing these effects.Two diagrams showing PROTAC WD6305 and RSM3 mechanisms targeting METTL3-METTL14 complex degradation and inhibition. (A) The design diagram of PROTAC WD6306, Reproduced from [99] with permission from Elsevier. © 2023 Elsevier Ltd; (B) The design diagram of RSM3, Reproduced from [100] with permission from Wiley. (Blue downward arrows indicate decreased proliferation and migration, whereas red upward arrows indicate increased inflammation and apoptosis.). FTO Inhibitors Meclofenamic Acid (MA) was first discovered as an FTO inhibitor through high-throughput screening. The study shows that MA selectively inhibits the demethylation activity of FTO while having minimal effect on ALKBH5. MA competitively binds to FTO and blocks its interaction with the m6A substrate, significantly increasing m6A levels in cells, demonstrating its potential as a functional probe for FTO.101 The discovery of MA not only provides a new tool for the biological study of FTO but also lays an important structural foundation for the development of more efficient and specific FTO inhibitors in the future. Based on the characteristics of MA, researchers developed its derivatives, FB23 and FB,23−27 with enhanced properties. FB23-2 selectively targets FTO, significantly affecting leukemia cells, particularly AML cells. It inhibits FTO’s demethylation activity on m6A, leading to an increase in m6A modifications within RNA. Additionally, FB23-2 suppresses the expression of MYC and CEBPA, both of which are upregulated by FTO (Figure 4A).7 This treatment promotes myeloid differentiation and induces apoptosis, resulting in cell cycle arrest at the G1 phase. In vivo studies show that FB23-2 delays leukemia progression, improves survival in xenograft mouse models, and reduces the population of leukemia stem cells, thereby enhancing its therapeutic potential for AML. Compared to MA, FB23-2 exhibits superior selectivity for FTO. DAC51 is a potent FTO inhibitor developed through rational optimization of previous FTO inhibitors such as FB23 and FB23-2. It was designed to improve selectivity and potency for FTO while maintaining favorable pharmacological properties. The mechanism of action of DAC51 involves inhibiting FTO’s demethylation activity on m6A,102 leading to increased m6A modifications in RNA, particularly in genes involved in glycolysis and immune evasion. By accumulating m6A-modified RNA, DAC51 reprograms tumor metabolism and enhances immune responses. Specifically, DAC51 promotes CD8+ T cell infiltration into tumors and boosts cytokine secretion such as IFN-gamma and granzyme B, which are critical for T cell-mediated tumor rejection. In addition, DAC51 significantly reduces glycolytic activity in tumor cells, further enhancing the effectiveness of T cells in the tumor microenvironment. Notably, DAC51 shows synergy with immune checkpoint inhibitors like anti-PD-L1, enhancing tumor control and improving the overall efficacy of immunotherapy (Figure 4B).102 Researchers have optimized the structure of FB23 by incorporating flexible basic side chains and other modifications to enhance the molecular framework, thereby improving its pharmacokinetic properties and cellular permeability. The resulting compound, ZLD115, significantly inhibits FTO’s m6A demethylation activity, leading to a marked increase in m6A modifications on RNA in AML cells. ZLD115 upregulates the expression of RARA and downregulates MYC, consistent with gene expression changes observed following FTO knockdown, indicating that its mechanism of action is mediated through FTO inhibition. AML cells treated with ZLD115 show a strong antiproliferative effect, highlighting its potential as an effective therapeutic agent.103 QP73 is a PROTAC degrader developed to target FTO for degradation in AML. The design process involved selecting FB23 as the warhead due to its strong affinity for FTO and combining it with a CRBN ligand and a flexible linker to create a heterobifunctional degrader. Structural optimization of QP73 enhanced its ability to induce FTO degradation via the ubiquitin-proteasome system in AML cells. In AML cell lines, QP73 induced FTO degradation in a dose-, time-, and CRBN-dependent manner, leading to a significant increase in m6A modifications, promoting myeloid differentiation and apoptosis. In xenograft models, QP73 effectively suppressed AML tumor growth and demonstrated superior antiproliferative effects (Figure 4C).104 In addition, the YANG research group developed several other FTO inhibitors, including Dac590, a tricyclic benzoic acid derivative. Dac590 exhibits nanomolar-level FTO inhibition and demonstrates potent antiproliferative effects in AML cell lines and primary leukemia cells. Mechanistic studies reveal that Dac590 exerts its antileukemia effects by inhibiting FTO and its downstream target genes. Notably, Dac590, as a potent oral FTO inhibitor, significantly suppressed leukemia progression and prolonged survival in in vivo models without inducing toxicity, highlighting its potential as a therapeutic agent for AML treatment (Figure 4D).105 Compound 8t is a novel FTO inhibitor based on an acylhydrazone scaffold, with structural optimization enhancing its selectivity and inhibitory activity toward FTO. This compound demonstrates significant antiproliferative effects in acute myeloid leukemia (AML) cell lines, with an IC50 value below 1 μM. It effectively inhibits FTO’s demethylation activity, leading to an increase in m6A modifications on RNA. Mechanistic studies indicate that 8t elevates m6A levels, which in turn impacts the expression of oncogenic genes regulated by FTO.106 Other researchers have sequentially identified FTO inhibitors FTO-04 and FTO-43N.107,108 FTO-43N was rationally designed through the optimization of the previously identified compound FTO-04, improving its potency and selectivity for FTO over its homolog ALKBH5, while maintaining favorable physicochemical properties. FTO-43N exhibited enhanced antiproliferative effects across various cancer cell lines, including glioblastoma, acute myeloid leukemia, and gastric cancer, in which FTO is overexpressed.108 Figure 4(A) Molecular structure of the FTO inhibitor FB23-2 and its mechanism of action in AML, Reproduced from [7] with permission from Elsevier. (B) Mechanism of action of the FTO inhibitor DC51 in tumor cells, Reproduced from [102] with permission from Elsevier. © 2021 Elsevier Inc. (C) Molecular structure and mechanism of action of the FTO inhibitor QP73, Reproduced from [104] under the Creative Commons CC BY-NC-ND 4.0 license. (D) Molecular structure and mechanism of action of the FTO inhibitor DAC590, Reproduced from [105] with permission from the American Chemical Society. The colors of the arrows do not have specific meanings. The direction of the arrows indicates the corresponding changes: upward arrows indicate an increase or upregulation, whereas downward arrows indicate a decrease or inhibition.A schematic of FTO inhibitor mechanisms in AML is depicted in four panels. Panel one shows AML cells treated with FB23-2, increasing ASB2 and RARA, while decreasing MYC and CEBPA, leading to drug response. Panel two contrasts Fto wild type, which boosts glycolysis and reduces immune responses, with Fto mutant, where FTO knockdown or DAC51 suppresses these factors, enhancing immune responses. Panel three illustrates QP73 as a PROTAC degrader linking FTO inhibitor to CRBN, causing FTO degradation, increasing m6A and inducing apoptosis. Western blots display FTO and GAPDH levels over time and dosage. Panel four shows DAC590 binding a protein pocket, inhibiting AML cells at IC50 equals 6.06 nM, raising m6A and ASB2/RARA while lowering c-Myc/CEBPA. Combined with DAC, it reduces DNMT1 and 5mC, demonstrating synergistic antileukemia effects and oral efficacy with prolonged survival in vivo.Four-panel schematic of FTO inhibitors FB23-2 comma QP73 comma DAC590 comma and DAC51 targeting m6A in AML cells. (A) Molecular structure of the FTO inhibitor FB23-2 and its mechanism of action in AML, Reproduced from [7] with permission from Elsevier. (B) Mechanism of action of the FTO inhibitor DC51 in tumor cells, Reproduced from [102] with permission from Elsevier. © 2021 Elsevier Inc. (C) Molecular structure and mechanism of action of the FTO inhibitor QP73, Reproduced from [104] under the Creative Commons CC BY-NC-ND 4.0 license. (D) Molecular structure and mechanism of action of the FTO inhibitor DAC590, Reproduced from [105] with permission from the American Chemical Society. The colors of the arrows do not have specific meanings. The direction of the arrows indicates the corresponding changes: upward arrows indicate an increase or upregulation, whereas downward arrows indicate a decrease or inhibition. ALKBH5 Inhibitors Based on the analysis of the ALKBH5 protein sequence, the cysteine residue at position C200 has been identified as a potential nucleophilic target for covalent modification. This cysteine residue has become a key focus for researchers aiming to develop ALKBH5 inhibitors, with several studies targeting C200 for the design of selective and effective small molecules. Compound 18L is a potent ALKBH5 inhibitor developed using a C200 covalent targeting strategy, designed to selectively target the cysteine residue (C200) of ALKBH5. It effectively inhibits ALKBH5 activity, leading to increased m6A modifications on RNA. Mechanistically, 18L promotes cell differentiation and induces apoptosis, exerting significant antileukemia effects in AML cell lines and xenograft mouse models. At a dose of 1 mg/kg, it suppressed tumor growth by approximately 66.3%, without noticeable toxicity, highlighting its potential as a therapeutic agent for AML treatment (Figure 5A).109 To target ALKBH5, the team employed virtual screening and structure-based optimization to identify W23-1006, a novel covalent inhibitor. This compound selectively covalently binds to Cys200 of ALKBH5, a nucleophilic residue identified as a key site for inhibition. W23-1006 demonstrated strong selectivity with IC50 values around 3.8 μM and minimal effect on related enzymes such as FTO and ALKBH3. Mechanistically, W23-1006 inhibits ALKBH5’s demethylation activity, leading to a significant increase in m6A levels on key RNA transcripts, such as fibronectin 1 (FN1), and disrupting downstream oncogenic signaling. In cellular assays, W23-1006 showed antiproliferative and antimigratory effects in triple-negative breast cancer (TNBC) cells. In vivo, the compound suppressed tumor growth and metastasis, demonstrating its potential as a therapeutic agent (Figure 5B).110 Representative m6A-targeted therapeutic agents and their major characteristics are summarized in Table 3. Table 3Representative m6A-Targeted Therapeutic Agents in CancerMolecular TargetInterventionMechanismCancer TypeExperimental ModelEfficacyDevelopment StageMETTL3STM2457Competitive inhibition at the SAM-binding siteAML, neuroblastoma, prostate cancerCell and animal modelsInhibits proliferation; induces differentiation/apoptosis; prolongs survivalPreclinicalMETTL3UZH2Competitive inhibition at the SAM-binding siteAMLCell modelsInhibits METTL3 activity and cell proliferationPreclinicalMETTL3CDIBAInhibits METTL3 catalytic activityCancer cellsCell modelsInhibits cell proliferationPreclinicalMETTL3EltrombopagInhibits METTL3 catalytic activityHematological cancersCell modelsInhibits cell growthPreclinicalMETTL3QuercetinInhibits METTL3 catalytic activityPancreatic, gastric cancerCell modelsInhibits growth and migrationPreclinicalMETTL3ElvitegravirSTUB1-mediated METTL3 degradationEsophageal squamous cell carcinoma (ESCC)Cell modelsReduces METTL3 levelsPreclinicalMETTL3 /METTL14WD6305VHL-recruiting degraderAMLCell modelsEnhances antiproliferative and pro-apoptotic effectsPreclinicalMETTL3RSM3Inhibits METTL3 enzymatic activityProstate, pancreatic cancerCell and animal modelsInhibits tumor growth and migration; induces apoptosisPreclinicalFTOFB23-2Inhibits FTO demethylase activityAMLCell and xenograft modelsPromotes differentiation/apoptosis; prolongs survivalPreclinicalFTODAC51Inhibits FTO demethylase activityCancerTumor and immune modelsSuppresses glycolysis; enhances CD8⁺ T-cell infiltration; synergizes with anti-PD-L1PreclinicalFTOZLD115Inhibits FTO demethylase activityAMLCell modelsInhibits proliferation; upregulates RARA and downregulates MYCPreclinicalFTOQP73CRBN-mediated FTO degradationAMLCell and xenograft modelsPromotes differentiation/apoptosis; suppresses tumor growthPreclinicalFTODac590Inhibits FTO demethylase activityAMLCell and animal modelsInhibits proliferation and leukemia progression; prolongs survivalPreclinicalFTO8tInhibits FTO demethylase activityAMLCell modelsInhibits proliferationPreclinicalFTOFTO-43NInhibits FTO demethylase activityGBM, AML, gastric cancerCell modelsEnhances antiproliferative activityPreclinicalALKBH518LCovalent inhibition at Cys200AMLCell and xenograft modelsPromotes differentiation/apoptosisPreclinicalALKBH5W23-1006Covalent inhibition at Cys200TNBCCell and tumor/metastasis modelsInhibits proliferation, migration, growth and metastasisPreclinical Figure 5(A) The structure of 18I. Bold text is used to highlight the in vivo antitumor efficacy (TGI) and the corresponding treatment dosage, Reproduced from [109] with permission from Wiley. (B) The design pathway of ALKBH5 covalent inhibitor W23-1006, Reproduced from [110] with permission from the American Chemical Society.The image A shows a left-to-right workflow starting from an in-house compound library of covalent small molecules. An arrow points to the ALKBH5 protein surface with the non-catalytic site C200 highlighted. A further arrow labeled structure optimization leads to compound 18I, whose key values are ALKBH5 IC subscript 50 equals 0.62 micromolar, FTO IC subscript 50 greater than 100 micromolar, NB4 cells IC subscript 50 equals 0.63 micromolar and NB4 in vivo tumor growth inhibition equals 76.8 percent at 2.5 mg per kg. The image B is enclosed in a dashed box and shows compound W23-1006 with ALKBH5 IC subscript 50 equals 3.848 micromolar and FTO IC subscript 50 equals 113.7 micromolar. An arrow labeled covalently binds to ALKBH5 C200 points to ALKBH5, blocking demethylation. A separate arrow then shows increased m superscript 6 A on FN1 mRNA leading to RNA degradation. The compound is noted to exert antitumor effect in vivo.Diagram: ALKBH5 inhibitor found via library screening, optimized to compound 18I and W23-1006 mechanism. Table 3Representative m6A-Targeted Therapeutic Agents in CancerMolecular TargetInterventionMechanismCancer TypeExperimental ModelEfficacyDevelopment StageMETTL3STM2457Competitive inhibition at the SAM-binding siteAML, neuroblastoma, prostate cancerCell and animal modelsInhibits proliferation; induces differentiation/apoptosis; prolongs survivalPreclinicalMETTL3UZH2Competitive inhibition at the SAM-binding siteAMLCell modelsInhibits METTL3 activity and cell proliferationPreclinicalMETTL3CDIBAInhibits METTL3 catalytic activityCancer cellsCell modelsInhibits cell proliferationPreclinicalMETTL3EltrombopagInhibits METTL3 catalytic activityHematological cancersCell modelsInhibits cell growthPreclinicalMETTL3QuercetinInhibits METTL3 catalytic activityPancreatic, gastric cancerCell modelsInhibits growth and migrationPreclinicalMETTL3ElvitegravirSTUB1-mediated METTL3 degradationEsophageal squamous cell carcinoma (ESCC)Cell modelsReduces METTL3 levelsPreclinicalMETTL3 /METTL14WD6305VHL-recruiting degraderAMLCell modelsEnhances antiproliferative and pro-apoptotic effectsPreclinicalMETTL3RSM3Inhibits METTL3 enzymatic activityProstate, pancreatic cancerCell and animal modelsInhibits tumor growth and migration; induces apoptosisPreclinicalFTOFB23-2Inhibits FTO demethylase activityAMLCell and xenograft modelsPromotes differentiation/apoptosis; prolongs survivalPreclinicalFTODAC51Inhibits FTO demethylase activityCancerTumor and immune modelsSuppresses glycolysis; enhances CD8⁺ T-cell infiltration; synergizes with anti-PD-L1PreclinicalFTOZLD115Inhibits FTO demethylase activityAMLCell modelsInhibits proliferation; upregulates RARA and downregulates MYCPreclinicalFTOQP73CRBN-mediated FTO degradationAMLCell and xenograft modelsPromotes differentiation/apoptosis; suppresses tumor growthPreclinicalFTODac590Inhibits FTO demethylase activityAMLCell and animal modelsInhibits proliferation and leukemia progression; prolongs survivalPreclinicalFTO8tInhibits FTO demethylase activityAMLCell modelsInhibits proliferationPreclinicalFTOFTO-43NInhibits FTO demethylase activityGBM, AML, gastric cancerCell modelsEnhances antiproliferative activityPreclinicalALKBH518LCovalent inhibition at Cys200AMLCell and xenograft modelsPromotes differentiation/apoptosisPreclinicalALKBH5W23-1006Covalent inhibition at Cys200TNBCCell and tumor/metastasis modelsInhibits proliferation, migration, growth and metastasisPreclinical Representative m6A-Targeted Therapeutic Agents in Cancer (A) The structure of 18I. Bold text is used to highlight the in vivo antitumor efficacy (TGI) and the corresponding treatment dosage, Reproduced from [109] with permission from Wiley. (B) The design pathway of ALKBH5 covalent inhibitor W23-1006, Reproduced from [110] with permission from the American Chemical Society. siRNA-Based Targeting of m6A Modifiers Beyond small molecules and macromolecule PROTAC, RNA interference (RNAi) offers a highly specific approach for targeting m6A regulators, The differences between small-molecule drugs and siRNA drugs are shown in Table 4. Small interfering RNAs (siRNAs) can selectively silence genes encoding m6A writers (METTL3, METTL14), erasers (FTO, ALKBH5), or readers (YTHDF1/2), modulating the epigenetic landscape of tumor cells. For example, METTL3-targeted siRNAs reduce m6A levels on oncogenic transcripts, impairing proliferation, migration, and invasion. FTO-specific siRNAs enhance m6A modification on genes involved in tumor metabolism and immune evasion, promoting T cell infiltration and improving immunotherapy responsiveness. ALKBH5-targeted siRNAs disrupt cancer stem cell maintenance and metastasis via m6A-dependent regulation of oncogenes. When combined with advanced delivery systems, such as lipid nanoparticles, exosomes, or engineered extracellular vesicles, siRNA-based therapeutics provide precise, low-toxicity modulation of m6A regulators, complementing chemical and macromolecule inhibitors and offering promising avenues for personalized cancer therapy. Table 4Comparison of Small Molecule and siRNA Therapeutics for m6A ModulationTypeTargetMechanismAdvantagesChallenges/LimitationsInhibitors and degraderMETTL3 (STM2457, UZH2, CDIBA, Eltrombopag, Quercetin, Elvitegravir)Competitive inhibition at SAM-binding site; reduce m6A levelsGood selectivity; effective in vivoLimited for protein-protein complex targets; possible resistance; some inhibitors with low selectivityFTO (MA, FB23-2, DAC51, ZLD115, QP73, Dac590, 8t, FTO-04, FTO-43N)Inhibit demethylase activity; PROTACs can induce degradationHigh selectivity; can synergize with immunotherapyMetabolism and tissue-specific delivery are limiting; long-term efficacy needs evaluationALKBH5 (18L, W23-1006)Inhibit demethylase activity, increasing m6A levelsHigh selectivity; strong antitumor effectDelivery to solid tumors challenging; stability needs improvementsiRNA/RNAi-based therapeuticsMETTL3, METTL14, FTO, ALKBH5, YTHDF1/2Target mRNA; gene silencing; reduce enzyme or reader levelsHighly specific; can target proteins difficult for chemical inhibitors; can be combined with nanoparticle or exosome deliveryLow stability in vivo; requires delivery systems; potential off-target effects and immune activation; higher production cost Table 4Comparison of Small Molecule and siRNA Therapeutics for m6A ModulationTypeTargetMechanismAdvantagesChallenges/LimitationsInhibitors and degraderMETTL3 (STM2457, UZH2, CDIBA, Eltrombopag, Quercetin, Elvitegravir)Competitive inhibition at SAM-binding site; reduce m6A levelsGood selectivity; effective in vivoLimited for protein-protein complex targets; possible resistance; some inhibitors with low selectivityFTO (MA, FB23-2, DAC51, ZLD115, QP73, Dac590, 8t, FTO-04, FTO-43N)Inhibit demethylase activity; PROTACs can induce degradationHigh selectivity; can synergize with immunotherapyMetabolism and tissue-specific delivery are limiting; long-term efficacy needs evaluationALKBH5 (18L, W23-1006)Inhibit demethylase activity, increasing m6A levelsHigh selectivity; strong antitumor effectDelivery to solid tumors challenging; stability needs improvementsiRNA/RNAi-based therapeuticsMETTL3, METTL14, FTO, ALKBH5, YTHDF1/2Target mRNA; gene silencing; reduce enzyme or reader levelsHighly specific; can target proteins difficult for chemical inhibitors; can be combined with nanoparticle or exosome deliveryLow stability in vivo; requires delivery systems; potential off-target effects and immune activation; higher production cost Comparison of Small Molecule and siRNA Therapeutics for m6A Modulation However, despite the therapeutic potential of these small-molecule and siRNA-based strategies, their clinical translation is still constrained by issues such as limited stability, poor pharmacokinetic properties, insufficient tumor selectivity, and inefficient delivery to tumor tissues. These limitations highlight the need for advanced delivery strategies capable of improving the stability, bioavailability, and tumor-specific accumulation of m6A-targeted therapeutics. Nanodelivery systems have therefore emerged as a promising approach to address these challenges and further enhance the therapeutic efficacy of m6A-targeted interventions. The Progress of m6A Drug Nanodelivery As discussed above, various small-molecule inhibitors and siRNA-based strategies have been developed to target m6A regulators, including METTL3, FTO, and ALKBH5. However, the therapeutic efficacy and clinical translation of these approaches are often limited by insufficient tumor selectivity, poor in vivo stability, unfavorable pharmacokinetic properties, and inefficient delivery to tumor tissues. These limitations provide a strong rationale for integrating m6A-targeted therapeutics with nanodelivery technologies. By improving drug stability, bioavailability, tumor accumulation, and controlled release, nanocarriers may overcome some of the delivery barriers associated with conventional m6A-targeted therapies and enhance their therapeutic efficacy. The following section summarizes recent advances in nanodelivery systems for m6A-targeted cancer therapy. The nanodelivery system has achieved significant results in the delivery of m6A inhibitors. The PLGA-STM-TAT nanodelivery system, developed in recent research, integrates multiple components to enhance the therapeutic potential of m6A inhibitors, particularly in the treatment of gastric cancer. The system is composed of a biodegradable PLGA core, which serves as the drug carrier, ensuring controlled drug release and stability. The STM2457, a small molecule inhibitor targeting the m6A methyltransferase METTL3, is encapsulated within the PLGA nanoparticles. The addition of TAT peptides, known for their cell-penetrating capabilities, significantly enhances cellular uptake, facilitating the delivery of the inhibitor into tumor cells. Furthermore, the system utilizes cancer cell membrane coatings and the YSA peptide, which specifically targets the EphA2 receptor overexpressed on gastric cancer cells, allowing for precise tumor targeting. The nanodelivery system demonstrates a multifaceted therapeutic mechanism. By inhibiting METTL3, it reduces m6A modification on key oncogenic RNA, thereby downregulating the expression of tumor-promoting genes such as c-MYC and BRD4, ultimately suppressing cancer cell proliferation. Moreover, the system exerts a synergistic effect by downregulating PD-L1, a critical immune checkpoint molecule, and enhancing anti-tumor immunity when used in combination with immune checkpoint inhibitors like anti-PD-1 antibodies (Figure 6A).14 Compared to traditional administration of the STM2457 inhibitor, the PLGA-STM-TAT nanodelivery system offers several advantages: it improves targeting efficiency to tumor tissues, enhances drug stability and bioavailability, and facilitates the synergistic immune response, which is difficult to achieve with conventional single-drug therapies. These properties underscore the potential of this nanodelivery platform for clinical applications, particularly in enhancing the efficacy of m6A inhibitors in cancer therapy and immunotherapy. A similar strategy has also been applied to FTO-targeted therapy. A multifunctional nanodrug based on mesoporous polydopamine (MPDA) nanoparticles was developed to enhance post-ablation immunotherapy of hepatocellular carcinoma. In this system, the FTO inhibitor FB23-2 was encapsulated within the mesoporous structure of MPDA, while mannose and maleimide groups were introduced onto the nanoparticle surface to facilitate dendritic cell targeting and tumor-associated antigen capture, respectively. Following thermal ablation, the nanodrug captured the released tumor-associated antigens and delivered them together with FB23-2 to tumor-infiltrating dendritic cells. FTO inhibition increased m6A modification levels, promoted dendritic cell maturation and antigen presentation, and enhanced CD8⁺ T-cell infiltration. Furthermore, combination with immune checkpoint blockade effectively suppressed distant tumor growth and lung metastasis. Collectively, this study demonstrates that nanodelivery of m6A-targeted inhibitors can be integrated with local tumor ablation and immunotherapy to enhance antitumor immunity and reduce tumor recurrence.111 Figure 6m6A-targeted drug delivery systems for cancer therapy. (A) Schematic diagram of STM delivery nanoparticles for targeted therapy of gastric cancer, Reproduced from [14] with permission from Elsevier. © 2025 Elsevier Ltd. (B) Schematic diagram of engineered extracellular vesicles targeting the m6A reader protein YTHDF1 for m6A epigenetic regulation and immunotherapy in gastric cancer, Reproduced from [112] with permission from Wiley. (C) Schematic diagram of ALKBH5 mRNA-loaded exosome-liposome hybrid nanoparticles inhibiting colorectal tumors, Reproduced from [113] with permission from the American Chemical Society. (D) pH-responsive lipid nanoparticles Lip@si-YTHDF2 inhibit hepatocellular carcinoma cell proliferation, Reproduced from [114] under the Creative Commons CC BY-NC-ND 4.0 license. The colors of the arrows (blue, black, and red) do not have specific meanings. The direction of the arrows indicates the corresponding changes: upward arrows indicate an increase or upregulation, whereas downward arrows indicate a decrease or inhibition.The image consists of four schematics illustrating m6A-targeted drug delivery systems for cancer therapy. A shows intracellular and extracellular processes involving METTL3, STM and PLGA-STM-DIR-TAT nanoparticles targeting gastric cancer cells. It highlights mRNA methylation, cell cycle regulation and tumor targeting via EphA2 and YSA peptides. B depicts engineered extracellular vesicles targeting YTHDF1 for immunotherapy in gastric cancer, showing interactions with macrophages, T cells and tumor cells. C illustrates ALKBH5 mRNA-loaded exosome-liposome hybrid nanoparticles inhibiting colorectal cancer progression by affecting RNA methylation and glycolysis. D presents pH-responsive lipid nanoparticles Lip@si-YTHDF2 inhibiting hepatocellular carcinoma cell proliferation, showing immune escape mechanisms and interactions with T cells and MDSCs.Four m6A-targeted drug delivery designs for cancer therapy, illustrating nanoparticle mechanisms. m6A-targeted drug delivery systems for cancer therapy. (A) Schematic diagram of STM delivery nanoparticles for targeted therapy of gastric cancer, Reproduced from [14] with permission from Elsevier. © 2025 Elsevier Ltd. (B) Schematic diagram of engineered extracellular vesicles targeting the m6A reader protein YTHDF1 for m6A epigenetic regulation and immunotherapy in gastric cancer, Reproduced from [112] with permission from Wiley. (C) Schematic diagram of ALKBH5 mRNA-loaded exosome-liposome hybrid nanoparticles inhibiting colorectal tumors, Reproduced from [113] with permission from the American Chemical Society. (D) pH-responsive lipid nanoparticles Lip@si-YTHDF2 inhibit hepatocellular carcinoma cell proliferation, Reproduced from [114] under the Creative Commons CC BY-NC-ND 4.0 license. The colors of the arrows (blue, black, and red) do not have specific meanings. The direction of the arrows indicates the corresponding changes: upward arrows indicate an increase or upregulation, whereas downward arrows indicate a decrease or inhibition. With the development of gene therapy, an increasing number of studies have shifted towards siRNA delivery systems, particularly in the regulation of m6A modification. Unlike traditional small molecule inhibitors, siRNA can target and silence specific genes, directly influencing the epigenetic mechanisms of tumor cells. A novel nano-drug delivery system based on engineered small extracellular vesicles (sEVs) was designed to deliver short interfering RNA (siRNA) targeting the m6A reader protein YTHDF1, with the aim of regulating m6A-related epigenetic mechanisms for gastric cancer treatment. The engineered sEVs were derived from RAW 264.7 macrophage cells, ensuring biocompatibility, low immunogenicity, and enhanced cellular uptake. To improve tumor targeting, the surface of the sEVs was functionalized with cyclic RGD peptides (c(RGDyC)), which specifically target integrin receptors overexpressed on tumor cells. Additionally, the sEVs were engineered to express high levels of CD47 to evade macrophage-mediated clearance, thus prolonging their circulation time in vivo. The system’s therapeutic mechanism involves the delivery of siRNA targeting YTHDF1, which silences the gene and disrupts the binding of YTHDF1 to m6A-modified RNA, thereby inhibiting the translation of key oncogenes such as FZD7. This leads to the inactivation of the Wnt/β-catenin signaling pathway, suppressing tumor cell proliferation and metastasis. Furthermore, the knockdown of YTHDF1 enhances the expression of the IFN-γ receptor and its downstream response, promoting a robust T cell-mediated anti-tumor immune response. The engineered sEVs also improve immune activation by increasing macrophage phagocytosis of tumor cells (Figure 6B).112 Similarly, a novel exosome-liposome hybrid nanoparticle (ELNP) system was developed to deliver ALKBH5 mRNA, aiming to regulate m6A modifications in tumor cells. The system utilizes a hybrid nanoparticle composed of exosomes, derived from RAW 264.7 macrophage cells, combined with liposomes for enhanced drug loading capacity and stability. To improve targeting efficiency, the nanoparticles are functionalized with folic acid (FA), which specifically targets overexpressed folate receptors on cancer cells. The incorporation of ALKBH5 mRNA into this system allows for the expression of the ALKBH5 protein, a critical m6A eraser, which removes excess m6A modifications from oncogenic RNAs, ultimately impacting the stability and translation efficiency of these molecules. The therapeutic mechanism of this system hinges on the downregulation of m6A modifications, which influences the expression of key oncogenes, such as FZD7, and inactivates the Wnt/β-catenin signaling pathway, leading to suppressed tumor cell proliferation and metastasis. Furthermore, the delivery of ALKBH5 mRNA enhances immune activation, promoting T cell-mediated anti-tumor responses, while reducing tumor glycolysis through the regulation of key metabolic pathways, such as the JMJD8/PKM2 axis (Figure 6C).113 YTHDF2 regulates the immune suppressive function of MDSCs through the m6A modification on MYC mRNA, thereby promoting immune escape in HCC. To achieve targeted inhibition of YTHDF2, researchers designed a pH-responsive lipid nanoparticle (Lip@si-YTHDF2) for delivering siRNA to specifically silence YTHDF2. In vitro experiments showed that Lip@si-YTHDF2 could effectively release siRNA in acidic environments (simulating the tumor microenvironment), and it achieved efficient cellular uptake and gene silencing in MDSCs. In in vivo studies, Lip@si-YTHDF2 significantly inhibited tumor growth, and its anti-tumor effect was further enhanced when used in combination with a PD-1 checkpoint inhibitor (Figure 6D).114 Beyond pH-responsive delivery, ROS-responsive nanoplatforms have also been explored to improve the delivery efficiency of m6A-targeted siRNA. A ROS-responsive polyethylenimine-phenylboronic acid-bovine serum albumin (PEI-PBA-BSA) nanoparticle was developed for targeted delivery of siMETTL3 in hepatocellular carcinoma. The nanoplatform effectively encapsulated and protected siMETTL3, while the phenylboronic acid moiety enabled ROS-responsive release in the tumor microenvironment, thereby enhancing intracellular siRNA delivery and METTL3 silencing. In vitro, PEI-PBA-BSA@siMETTL3 significantly inhibited hepatocellular carcinoma cell proliferation, migration, invasion, and stemness. In vivo, the nanoplatform effectively suppressed tumor growth, with a tumor inhibition rate of up to 68%, while exhibiting good biosafety. These findings highlight the potential of ROS-responsive nanocarriers to improve the stability and delivery efficiency of siRNA and enhance the therapeutic effects of m6A-targeted gene silencing.115 Representative nanodelivery systems for m6A-targeted therapy are summarized in Table 5. Table 5Representative Nanodelivery Systems for m6A-Targeted Cancer TherapyCarrier TypeTherapeutic Cargom6A TargetTargeting LigandCancer TypeMain OutcomeToxicityPLGA nanoparticles with TAT and tumor-cell membrane/YSA coatingSTM2457METTL3YSA peptide; tumor-cell membraneGastric cancerEnhances tumor accumulation; inhibits tumor growth; enhances anti-PD-1 responseNegligible systemic toxicityMannose/maleimide-functionalized MPDA nanoparticlesFB23-2 and tumor-associated antigensFTOMannoseHepatocellular carcinomaPromotes DC maturation and T-cell infiltration; inhibits tumor recurrence and metastasisNegligible systemic toxicityEngineered small extracellular vesicles (sEVs)si-YTHDF1YTHDF1c(RGDyC) peptide; CD47Gastric cancerEnhances gene silencing; inhibits proliferation and metastasis; activates antitumor immunityNegligible systemic toxicityExosome–liposome hybrid nanoparticles (ELNPs)ALKBH5 mRNAALKBH5Folic acid (FA)Colorectal cancerRestores ALKBH5 expression; suppresses tumor growth and metastasis; enhances antitumor immunityNegligible systemic toxicitypH-responsive lipid nanoparticlessi-YTHDF2YTHDF2pH-responsive tumor microenvironmentHepatocellular carcinomaEnhances siRNA release and gene silencing; inhibits tumor growth; synergizes with anti-PD-1Negligible systemic toxicityROS-responsive PEI-PBA-BSA nanoparticlessiMETTL3METTL3Phenylboronic acidHepatocellular carcinomaEnhances siRNA delivery and METTL3 silencing; inhibits tumor growth and metastasisNegligible systemic toxicity Table 5Representative Nanodelivery Systems for m6A-Targeted Cancer TherapyCarrier TypeTherapeutic Cargom6A TargetTargeting LigandCancer TypeMain OutcomeToxicityPLGA nanoparticles with TAT and tumor-cell membrane/YSA coatingSTM2457METTL3YSA peptide; tumor-cell membraneGastric cancerEnhances tumor accumulation; inhibits tumor growth; enhances anti-PD-1 responseNegligible systemic toxicityMannose/maleimide-functionalized MPDA nanoparticlesFB23-2 and tumor-associated antigensFTOMannoseHepatocellular carcinomaPromotes DC maturation and T-cell infiltration; inhibits tumor recurrence and metastasisNegligible systemic toxicityEngineered small extracellular vesicles (sEVs)si-YTHDF1YTHDF1c(RGDyC) peptide; CD47Gastric cancerEnhances gene silencing; inhibits proliferation and metastasis; activates antitumor immunityNegligible systemic toxicityExosome–liposome hybrid nanoparticles (ELNPs)ALKBH5 mRNAALKBH5Folic acid (FA)Colorectal cancerRestores ALKBH5 expression; suppresses tumor growth and metastasis; enhances antitumor immunityNegligible systemic toxicitypH-responsive lipid nanoparticlessi-YTHDF2YTHDF2pH-responsive tumor microenvironmentHepatocellular carcinomaEnhances siRNA release and gene silencing; inhibits tumor growth; synergizes with anti-PD-1Negligible systemic toxicityROS-responsive PEI-PBA-BSA nanoparticlessiMETTL3METTL3Phenylboronic acidHepatocellular carcinomaEnhances siRNA delivery and METTL3 silencing; inhibits tumor growth and metastasisNegligible systemic toxicity Representative Nanodelivery Systems for m6A-Targeted Cancer Therapy Outlook and Challenges Although m6A-targeted therapy shows great potential in cancer treatment, it still faces numerous challenges. First, the high dynamic nature and environmental dependence of m6A modifications require precise spatiotemporal control of treatment strategies. The modification state of m6A varies in different physiological environments and cell types, and its reversibility and dynamism increase the complexity of intervention.116 Currently, there are few types of m6A inhibitors under development, and their efficacy is generally poor. The bioavailability and effective concentration of these drugs are limited, leading to suboptimal therapeutic effects. Furthermore, due to a lack of sufficient selectivity, these inhibitors may affect normal cells, causing unnecessary side effects.117 To avoid off-target effects and non-specific actions, developing more types of inhibitors and precisely controlling the timing and targeting of interventions have become significant challenges in therapy.117 For m6A-targeted nanotherapies, incomplete tumor targeting may further contribute to off-target effects, while tumor heterogeneity may result in different m6A regulatory patterns and therapeutic responses among patients or within different tumor regions. In addition, the pharmacokinetic behavior of nanotherapies, including biodistribution, clearance, and drug release, requires further optimization. Secondly, the complexity of the m6A regulatory network means that targeting a single point may trigger compensatory responses. m6A modification involves multiple regulatory factors and biological processes, and intervening with only a single enzyme or molecule may not be sufficient to fully regulate the entire modification process.116 Moreover, the long-term safety of repeated nanoparticle administration remains insufficiently characterized, particularly regarding tissue accumulation, immune responses, and potential toxicity of nanomaterials or their degradation products. Finally, there is currently a lack of reliable biomarkers to predict patients’ responses to m6A-targeted therapy. Tumor heterogeneity and the complex regulation of m6A further complicate patient selection, highlighting the need for reliable predictive biomarkers. Moreover, the clinical translation of m6A-targeted nanotherapies remains limited by the lack of standardized manufacturing processes and reproducible quality control. Most available evidence is derived from cellular and animal studies, and clinical validation of their efficacy, optimal dosing, pharmacokinetics, and long-term safety remains limited. The current developmental status and major translational limitations of these therapeutic strategies are summarized in Table 6. Table 6Current Status and Major Translational Limitations of m6A-Targeted Therapeutic StrategiesTherapeutic StrategyRepresentative ApproachesCurrent StatusMajor Translational Limitationsm6A methylation inhibitorsMETTL3, FTO, ALKBH5 inhibitorsPreclinicalLimited selectivity and bioavailability; off-target effects; lack of clinical validationm6A-targeted nanotherapyNanoparticle-based deliveryPreclinicalTumor heterogeneity; pharmacokinetic limitations; long-term safety; manufacturing reproducibilitym6A-targeted protein degradationPROTACs, peptide-based degradersPreclinicalDelivery and pharmacokinetic challenges; limited long-term safety and clinical evidence Table 6Current Status and Major Translational Limitations of m6A-Targeted Therapeutic StrategiesTherapeutic StrategyRepresentative ApproachesCurrent StatusMajor Translational Limitationsm6A methylation inhibitorsMETTL3, FTO, ALKBH5 inhibitorsPreclinicalLimited selectivity and bioavailability; off-target effects; lack of clinical validationm6A-targeted nanotherapyNanoparticle-based deliveryPreclinicalTumor heterogeneity; pharmacokinetic limitations; long-term safety; manufacturing reproducibilitym6A-targeted protein degradationPROTACs, peptide-based degradersPreclinicalDelivery and pharmacokinetic challenges; limited long-term safety and clinical evidence Current Status and Major Translational Limitations of m6A-Targeted Therapeutic Strategies To address the clinical challenges faced by m6A-targeted therapy, future research should focus on several key directions to enhance treatment efficacy and facilitate clinical translation. First, high-throughput screening (HTS) technology provides a powerful tool for drug discovery, enabling the rapid screening of large numbers of compounds to identify m6A-modifying inhibitors with stronger efficacy and higher selectivity, thus overcoming the limitations of existing drugs and improving cancer treatment outcomes.118 Second, the introduction of artificial intelligence (AI) has brought revolutionary progress to drug design. By simulating and predicting molecular interactions, AI can accelerate the drug discovery process and optimize the structure of m6A-targeted drugs through deep learning, enhancing their selectivity and stability, significantly shortening the new drug development cycle, and increasing the success rate.119 Third, m6A degraders, including PROTACs and peptide-based degraders, provide a promising strategy to eliminate m6A regulators at the protein level, rather than merely inhibiting enzymatic activity. By targeting METTL3, FTO, or ALKBH5 for proteasomal degradation, these compounds can achieve more potent and sustained suppression of oncogenic m6A signaling, potentially overcoming drug resistance associated with conventional inhibitors. Furthermore, nanoparticle delivery systems offer a new approach to cancer-targeted therapy. By precisely delivering m6A-targeted drugs, nanoparticles can increase drug concentration at tumor sites while avoiding side effects on normal tissues. The vigorous development of new nanoparticle delivery systems will further enhance their targeting, stability, and drug payload capacity, optimizing treatment efficacy. Lastly, personalized treatment is gradually becoming a new trend in cancer therapy. By combining the molecular features of m6A modifications and detecting changes in m6A in tumors, personalized treatment plans can be tailored for patients, improving treatment efficacy and reducing unnecessary side effects. Through these innovative approaches, m6A-targeted therapy is expected to achieve more efficient and precise clinical translation (Figure 7). Figure 7Current challenges and future directions for m6A drugs.The infographic is split into Challenges and Future Directions. Challenges include: 1. Poor selectivity causing toxicity due to off-target effects. 2. Single-target inhibitors may be ineffective due to the complex m6A regulation involving multiple proteins and pathways. 3. Lack of predictive biomarkers hinders patient stratification and treatment evaluation. Future Directions suggest: 1. Using AI and high-throughput screening to optimize and discover inhibitors. 2. Enhancing delivery systems with nanomaterials for better efficiency and targeting. 3. Combining m6A-targeted therapies with other treatments for personalized and synergistic effects.An infographic comparing challenges and future directions in m6A drug development. Current challenges and future directions for m6A drugs. Summary This review explores the research progress of m6A methylation modification in cancer therapy, with particular emphasis on its molecular mechanisms, targeted drug development, and the application of nano-delivery technologies. m6A modification significantly influences the onset, progression, and drug resistance of cancer by regulating key processes such as RNA stability, translation, and transcription. Recent studies have established m6A regulators as promising therapeutic targets, with small-molecule inhibitors and RNA-based strategies showing antitumor activity in preclinical models. Importantly, the therapeutic potential of these approaches is closely linked not only to the activity of m6A-targeted agents but also to their stability, pharmacokinetic properties, and tumor-specific delivery. Nanodelivery systems therefore provide a complementary strategy to improve drug exposure, tumor accumulation, and selectivity. However, most current evidence remains preclinical, and clinical validation of m6A-targeted therapies and their nanodelivery systems is still limited. Key translational challenges include improving the specificity and stability of therapeutic agents, achieving reproducible tumor-selective delivery, clarifying the context-dependent functions of m6A regulation, and establishing reliable biomarkers for patient selection and treatment response. Future research must focus on optimizing nano-carriers, refining targeting mechanisms, and overcoming clinical translation barriers. Overall, the integration of m6A-targeted therapeutics with nanodelivery represents a promising strategy for improving therapeutic exposure and tumor selectivity; however, rigorous pharmacological, safety, and clinical studies are required to facilitate clinical translation and ultimately provide more personalized and effective treatment options for cancer patients.